SMN2 and proximal spinal muscular atrophy: The experiments reported here examine the factors affecting SMN protein signal variability in a peripherally accessible cell matrix that is expected to be a critical pharmacodynamic biomarker for imminent or ongoing drug trials for SMA [15], [31], [32].